Inhibikase Therapeutics (IKT) Current Deferred Revenue (2020 - 2022)

Inhibikase Therapeutics (IKT) has 3 years of Current Deferred Revenue data on file, last reported at $23683.0 in Q3 2022.

• Current Deferred Revenue for Q3 2022 came in at $23683.0, changed N/A year-over-year; the trailing twelve-month figure through Sep 2022 was $23683.0 (changed N/A YoY), and the FY2020 annual result was $2.3 million, changed N/A from the prior year.
• Current Deferred Revenue held at $23683.0 in Q3 2022 per IKT's latest filing, from $23684.0 in the prior quarter.
• Over five years, Current Deferred Revenue peaked at $2.3 million in Q4 2020 and troughed at $23683.0 in Q3 2022.
• A 3-year average of $753415.2 and a median of $142619.0 in 2021 frame the typical range for Current Deferred Revenue.
• On a YoY basis, Current Deferred Revenue climbed as much as 83.39% in 2022 and fell as far as 83.39% in 2022.
• A 3-year view of Current Deferred Revenue shows it stood at $2.3 million in 2020, then sank by 93.87% to $142619.0 in 2021, then slumped by 83.39% to $23683.0 in 2022.
• Business Quant data shows IKT's Current Deferred Revenue at $23683.0 in Q3 2022, $23684.0 in Q2 2022, and $142619.0 in Q2 2021.